Universidad de Zaragoza Repository

Resumen: Since amyotrophic lateral sclerosis (ALS) was discovered and described in 1869 as a neurodegenerative disease in which motor neuron death is induced, a wide range of biomarkers have been selected to identify therapeutic targets. ALS shares altered molecular pathways with other neurodegenerative diseases, such as Alzheimer’s, Huntington’s, and Parkinson’s diseases. However, the molecular targets that directly influence its aggressive nature remain unknown.What is the first link in the neurodegenerative chain of ALS that makes this disease so peculiar? In this review, we will discuss the progression of the disease from the viewpoint of the potential biomarkers described to date in human and animal model samples. Finally, we will consider potential therapeutic strategies for ALS treatment and future, innovative perspectives.
Idioma: Inglés
DOI: 10.1155/2014/925101
Año: 2014
Publicado en: BioMed Research International 2014 (2014), 925101 [12 pp]
ISSN: 2314-6133
Factor impacto JCR: 1.579 (2014)
Categ. JCR: MEDICINE, RESEARCH & EXPERIMENTAL rank: 85 / 123 = 0.691 (2014) - Q3 - T3
Categ. JCR: BIOTECHNOLOGY & APPLIED MICROBIOLOGY rank: 107 / 163 = 0.656 (2014) - Q3 - T2
Financiación: info:eu-repo/grantAgreement/ES/FIS/PI10-0178
Financiación: info:eu-repo/grantAgreement/ES/UZ/UZ2012-BIO-02-210-155
Tipo y forma: Article (Published version)
Área (Departamento): Área Genética (Dpto. Anatom.,Embri.Genét.Ani.)

You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Exportado de SIDERAL (2020-10-23-13:53:36)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Articles